In addition to the well-known role of mast cells in immunity to multi-cellular parasites and in the pathogenesis of allergy and asthma, the importance of mast cells in the immune defense against bacteria and viruses is increasingly being recognized. Their location in the skin, gut, and airways puts mast cells in an ideal location to encounter and respond to pathogens, and in order to perform this function, these cells express a variety of pattern recognition receptors, including Toll-like receptors (TLRs). Mast cells respond to TLR ligands by secreting cytokines, chemokines, and lipid mediators, and some studies have found that TLR ligands can also cause degranulation, although this finding is contentious.

The TLRs are a family of receptors which recognize a wide variety of pathogen-associated molecular patterns (PAMPs; Akira et al., 2006). Signaling via these receptors guides the immune system to mount the correct response to an invading pathogen, or to a harmless commensal, by a process which is not well understood (Blader and Sander, 2012).

More work has been carried out to determine the signaling pathways triggered by the TLR receptors and the consequences of their ligation (Lu et al., 2008; Akira, 2009; Kawai and Akira, 2010). This review aims to address what is known about the responses of mast cells to TLR ligands and the signaling pathways involved. Given the location of mast cells at sites exposed to the environment, the response of these cells to TLR ligands must be carefully regulated. The known mechanisms behind this regulation are also reviewed here.

**Keywords:** cytokine, innate, mast cells, review, signaling, TLRs

---

**INTRODUCTION**

Host cells utilize a variety of germline encoded receptors termed pathogen recognition receptors (PRRs), including the Toll-like receptors (TLR) and nucleotide-binding oligomerization domain (NOD) proteins, to recognize pathogens. These receptors allow the innate immune system to identify invading bacteria by their expression of pathogen-associated molecular patterns (PAMPs; Akira et al., 2006). Signaling via these receptors guides the immune system to mount the correct response to an invading pathogen, or to a harmless commensal, by a process which is not well understood (Blader and Sander, 2012).

Mast cells have traditionally been known for their roles in allergy and immunity to multi-cellular parasites (Metcalfe et al., 1997) but increasingly the crucial roles that they play in immune defense against bacteria and viruses are being recognized (Marshall, 2004; Abraham and St John, 2010). Mast cells are able to recognize pathogens via their expression of PRRs and by binding to antibodies with the FcRs (Abraham and St John, 2010). This review will focus on TLR expression, function and signaling, since the TLRs are the best studied PRR on mast cells.

**Abbreviations:** AC, adenylate cyclase; BMMC, bone marrow-derived mast cell; Btk, Bruton’s tyrosine kinase; CBMC, cord blood-derived mast cell; cysLT, cysteinyl leukotriene; FSDMC, fetal skin-derived mast cells; IFN, interferon; IGF-1, insulin-like growth factor-1; IHC, immunohistochemistry; LBP, LPS-binding protein; MD-2, myeloid differentiation-2; n.d., not determined; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C.

**TLR EXPRESSION ON MAST CELLS**

Several studies have been undertaken on murine and human mast cells isolated ex vivo, or differentiated from stem cells, as...
Table 1 | The main TLR ligands (adapted from Akira et al., 2006; Lee et al., 2012).

| TLR | Physiological ligands | Synthetic ligands |
|-----|-----------------------|-------------------|
| TLR1-2 | Tricatilated lipopeptides (bacteria and mycobacteria) | Pam3CSK4 |
| TLR2 | Peptidoglycan (gram positive bacteria), phospholipomannan (Candida albicans), tigP-mucins (Trypanosoma), haemagglutinin (mice villus), points (Waisman), liposaccharidomannan (mycobacteria), glucuronoxylomannan (Cryptococcus neoformans), HMGBl (host) | \( \text{CpG-ODN} \) |
| TLR2-6 | Dicatilated lipopeptides (Mycoplasma), LTA (Group B Streptococcus), zymosan | SFL1, MALP-2, Pam3CSK4 |
| TLR3 | dsRNA (viruses) | Poly(I:C) |
| TLR4 | LPS (Gram-negative bacteria), VSV glycoprotein G, RSV fusion protein, MMTV envelope protein, mannan (Candida albicans), glucuronoxylomannan (Cryptococcus neoformans), glycosylinositolphosphatidylinositol (Trypanosoma), HSPl60, HSPl70, fibrinogen, HMGB1 (all host proteins), nickel | \( \text{Imidazoquinoline compounds: imiquimod, resiquimod,} \) |
| TLR5 | Flagellin (Flagellated bacteria) | Resiquimod |
| TLR7 | ssRNA (RNA viruses) | \( \text{R848} \) |
| TLR8 | ssRNA (RNA viruses) | \( \text{FSL1} \) |
| TLR9 | CpG-DNA (bacteria and mycobacteria), DNA (viruses), haemoplasmin (Plasmodium) | \( \text{CpG-A, CpG-B and CpG-C ODNs} \) |

well as on mast cell lines to establish which TLRs are expressed. The expression of TLR2 by mast cells has been studied in more detail and it has been suggested that bone marrow-derived mast cell (BMMC) do not express the whole TLR2 protein but rather a truncated protein lacking the intracellular signal-domain (Mrabet-Dahbi et al., 2009). Despite this, a range of studies have determined that mast cells are able to respond to TLR2 ligands, as discussed below, and this may be due to the fact that the truncated TLR2 is still able to form heterodimers (Mrabet-Dahbi et al., 2009).

The expression of TLR1–10 with the exception of TLR8 has been assessed in many studies. Expression of TLR1, 4, 6, or 9 has been demonstrated on murine mast cells (McCurdy et al., 2001; Supajatura et al., 2001; Masuda et al., 2002; Ikeda and Funaba, 2003; Matsushima et al., 2004; Li et al., 2009; Mrabet-Dahbi et al., 2009). Expression of TLR3 has not been demonstrated on murine mast cells (McCurdy et al., 2001; Supajatura et al., 2001; Ikeda and Funaba, 2003; Matsushima et al., 2004).

Expression of TLR1–10 with the exception of TLR8 has been identified on human mast cells, although some studies were unable to identify TLR1, 4, 6, or 9 (McCurdy et al., 2003; Okumura et al., 2003; Varadarajalu et al., 2003; Kulka et al., 2004; Kulk and Metzcal, 2006; Yoshikai et al., 2007). TLR expression on the mast cell lines LAD2, HMC-1, and MC-9 has been assessed with varied results in different studies (McCurdy et al., 2001; Supajatura et al., 2001; Ikeda and Funaba, 2003; Matsushima et al., 2004). Expression of TLR1 and TLR2 has been studied in more detail and it has been suggested that bone marrow-derived mast cell (BMMC) do not express the whole TLR2 protein but rather a truncated protein lacking the intracellular signal-domain (Mrabet-Dahbi et al., 2009). Despite this, a range of studies have determined that mast cells are able to respond to TLR2 ligands, as discussed below, and this may be due to the fact that the truncated TLR2 is still able to form heterodimers (Mrabet-Dahbi et al., 2009).
Table 2 | TLR expression by mast cells.

| Murine | Human | Cell line |
|--------|--------|-----------|
| TLR1  | BMMC mRNA¹ | − lung mRNA² | + HMC-1 mRNA and protein³ |
|       | + FSDMC mRNA¹ | − skin mRNA² | − LAD2 mRNA and protein⁴ |
|       | + PBDMC mRNA and protein³ | + PBDMC mRNA and protein³ |
|       | + CD3D mRNA⁴ | + CD3D mRNA⁴ |
| TLR2  | − BMTC mRNA⁵−⁹ | + lung mRNA⁶ | − HMC-1 mRNA and protein⁷ |
|       | + FSDMC mRNA¹ | + lung protein⁶ | + LAD2 mRNA and protein⁸,⁹ |
|       | + BMTC protein⁵ | − skin mRNA² | + MC-9 mRNA⁷ |
|       | + PBDC mRNA and protein⁹ | + PBDC mRNA and protein³ |
|       | + CD3D mRNA⁴ | + CD3D mRNA⁴ |
| TLR3  | − BMTC mRNA¹ | + lung mRNA² | + LAD1 protein¹ |
|       | + FSDMC mRNA¹ | + skin mRNA² | + LAD2 mRNA and protein⁹ |
|       | − PBDC mRNA and protein³ | + PBDC mRNA and protein³ |
|       | + bone marrow⁹ | + bone marrow⁹ |
| TLR4  | − BMTC mRNA⁵−⁹,¹⁰ | − lung mRNA⁶ | − HMC-1 mRNA and protein⁷ |
|       | + BMTC protein⁵−⁹ | + skin mRNA² | + LAD2 mRNA and protein⁹ |
|       | + FSDMC mRNA and protein¹ | + PBDC mRNA and protein¹ |
|       | + peritoneal protein¹ | + PBDC mRNA and protein¹ |
|       | + CD3D mRNA⁴ | + CD3D mRNA⁴ |
| TLR5  | − BMTC mRNA⁵−⁹ | − lung mRNA² | + HMC-1 mRNA and protein⁷ |
|       | − FSDMC mRNA¹ | − skin mRNA² | + LAD2 mRNA and protein⁹ |
|       | − PBDC mRNA and protein³ | + PBDC mRNA and protein³ |
|       | − peritoneal protein¹ | − PBDC mRNA and protein³ |
| TLR6  | − BMTC mRNA⁵−⁹ | − lung mRNA² | + HMC-1 mRNA and protein⁷ |
|       | + FSDMC mRNA¹ | − skin mRNA² | + LAD2 mRNA and protein⁹ |
|       | − PBDC mRNA and protein³ | + PBDC mRNA and protein³ |
|       | − skin mRNA² | + PBDC mRNA and protein³ |
| TLR7  | − BMTC mRNA¹ | + lung mRNA² | + HMC-1 mRNA and protein⁷ |
|       | − FSDMC mRNA¹ | + skin mRNA² | + LAD2 mRNA and protein⁹ |
|       | − PBDC mRNA and protein³ | + PBDC mRNA and protein³ |
| TLR8  | − BMTC mRNA¹ | − lung mRNA² | + HMC-1 mRNA and protein⁷ |
|       | − FSDMC mRNA¹ | − skin mRNA² | + LAD2 mRNA and protein⁹ |
|       | − PBDC mRNA and protein³ | − PBDC mRNA and protein³ |
| TLR9  | − BMTC mRNA¹ | − lung mRNA² | + HMC-1 mRNA and protein⁷ |
|       | + FSDMC mRNA¹ | − skin mRNA² | + LAD2 mRNA and protein⁹ |
| TLR10 | No murine homolog | + lung mRNA² | None tested |

TLR expression on mast cells is summarized. The references are indicated by superscript numbers: ¹Matsushima et al., 2004; ²Kulka and Metcalfe, 2006; ³Kulka et al., 2004; ⁴McCurdy et al., 2001; ⁵Fukuda et al., 2000; ⁶Kulka and Fumbei, 2004; ⁷McCurdy et al., 2001; ⁸D’Souza et al., 2001; ⁹Mekbel-Dahbi et al., 2009; ¹⁰Supajutura et al., 2001; ¹¹Fukuda et al., 2002; ¹²Matsuda et al., 2002.

Of these three agonists, only LTA-induced PGD2 production in PCDMC (Mikheev-Dahbi et al., 2009; Figure 1). In human cord blood-derived mast cells (CBMC), stimulation with zymosan or PGN caused GM-CSF, IL-1β, LTB4, and LTC4 production (Olynych et al., 2006). Another study also identified differences between the mediators released upon different TLR ligands stimulation: PGN, zymosan, and Pam3Cys caused GM-CSF and IL-1β secretion whereas LPS did not; and PGN and zymosan...
FIGURE 1 | Mast cell secretory responses to TLR ligation. A diagram showing the molecules secreted by mast cells upon TLR ligation. The cytokines, chemokines, and lipid mediators released upon TLR ligand stimulation are summarized for murine BMMC, PCDMC, FSDMC, and human mast cells. Where there is discrepancy in the literature, molecules are shown in grey. *indicates instances where it has been demonstrated with the use of TLR-deficient cells or blocking antibodies that the ligand is acting via the indicated receptor.

FIGURE 2 | TLR signaling in the mast cell. A scheme illustrating the signaling pathways triggered by TLR ligation in the mast cell. Where there is evidence in the literature for the involvement of a particular protein, the protein is filled in black. Proposed molecules are in grey (adapted from Akira et al., 2006; Lu et al., 2008; Park et al., 2009). The activation of PI3K via c-kit or FcεRI stimulation is shown, with its inhibitory and activating effects on MAPK activation.

Peptidoglycan has been demonstrated to induce migration of peritoneal rat mast cells after a short treatment with TNFα (Brzezinska-Blaszczyk and Rdzany, 2007), and in a later publication, LPS and PGN both caused migration of the cells after treatment with IL-6 or CCL5/RANTES, respectively (Wierzbicki and Brzezinska-Blaszczyk, 2009). The mechanism behind these effects is as yet unknown, but it has been suggested that IL-6 and CCL5/RANTES may modulate TLR expression on the mast cells (Wierzbicki and Brzezinska-Blaszczyk, 2009). The ability of TLR agonists to cause mast cell migration in vivo would allow PAMPs or
endogenous TLR ligands produced upon tissue damage to recruit mast cells to sites of infection or inflammation.

TLR3 expression has been more readily detected on human than murine mast cells (see Table 1) and human PBDMC respond to flagellin (a TLR5 ligand) by secreting IL-1β and TNFα, demonstrating that the receptor is functional on these cells (Kulka et al., 2004; Figure 1). To our knowledge, flagellin has not been shown to cause cytokine secretion from murine mast cells, in agreement with the lack of detectable expression of TLR5 on the cells (McCurdy et al., 2001; Supajatura et al., 2001; Ikeda and Funaba, 2003; Matsushima et al., 2004).

Mast cell responses to intracellular TLRs

Double-stranded RNA molecules, such as polyIC, are used as a synthetic mimic of viral RNA (see Table 1) and cause IFNα and IFNβ secretion from human PBDMC and murine BMMC (Kulka et al., 2004). This response was partially blocked with anti-TLR3 antibodies and in TLR3−/− BMMC, suggesting that the receptor is involved in the detection of the RNA (Kulka et al., 2004). A different group found that murine FSDMC responded far more robustly to polyIC than BMMC, secreting IL-6, TNFα, CCL2/MIP-1α, CXCL2/MIP-2, and CCL5/RANTES which was in agreement with the greater TLR3 expression by FSDMC than BMMC (Matsushima et al., 2004). In a recent study using BMMC, no IL-6, TNFα or IFNα/β production was observed upon polyIC treatment (Kreck et al., 2011; Figure 1). The ability of BMMC to respond to TLR3 stimulation is, therefore, somewhat controversial, although mast cells from other sources clearly do respond (Kulka et al., 2004; Matsushima et al., 2004). These findings may reflect the more immature phenotype of BMMC.

Murine BMMC have been found to respond to bacterial but not mammalian DNA, and to synthetic oligonucleotides containing an unmethylated cytosine followed by a guanosine (CpG motif), by secreting IL-6 and TNFα (Zhu and Marshall, 2001). MC/9 cells were also found to respond to CpG-containing oligonucleotides by secreting IL-6 and TNFα, and the response of BMMC was greater when newer generations of CpG sequences were included in the oligonucleotides (Zhu and Marshall, 2001). These treatments were not found to induce mast cell degranulation or the secretion of GM-CSF, IL-4, IL-12, or IFNγ (Zhu and Marshall, 2001). A later study comparing BMMC and FSDMC found that TLR9 was expressed by FSDMC but not BMMC, and demonstrated TNFα, IL-6, CCL2/MIP-1α, CXCL2/MIP-2, and CCL5/RANTES secretion by FSDMC but not BMMC treated with CpG-containing oligonucleotides (Matsushima et al., 2004; Figure 1).

The TLR7 agonist, R848, caused secretion of IL-6 and TNFα and also the chemokines CCL2/MIP-1α and CXCL2/MIP-2 from FSDMC but not BMMC, and TLR7 expression was far higher in FSDMC (Matsushima et al., 2004). In spite of this, R848 stimulation of BMMC did lead to some CCL5/RANTES production (Matsushima et al., 2004; Figure 1), therefore murine mast cells appear to respond to TLR7 agonists, in agreement with their expression of the receptor (see Table 2).

A study using bovine PBDMC found that CpG-containing oligonucleotides stimulated cells to produce IFNα, IL-1β, TNFα, and cysteinyl leukotriene (Kulka et al., 2004). CpG-containing oligonucleotides activate TLR9 therefore these data suggest that in addition to expressing TLR9 (see Table 2), both human and murine mast cells are able to respond to TLR9 ligands by secreting cytokines and lipid mediators. The sensitivity of mast cells to TLR7 and TLR9 agonists would presumably assist in the immune defense against bacteria, viruses, and Plasmodium (see Table 1).

Fetal skin-derived mast cells express higher levels of TLR3, TLR7, and TLR9 and respond more potently to agonists of these receptors than BMMMC (Matsushima et al., 2004), in a similar manner to the greater response of FSDMC than BMMMC to TLR2 and 4 agonists (Mrabet-Dahbi et al., 2009). These results are likely a reflection of the immaturity of BMMMC and suggest that responses to some TLRs are better studied in mast cell models other than BMMMC (Matsushima et al., 2004; Mrabet-Dahbi et al., 2009).

Work performed in other immune cells has demonstrated that TLR3 and 9 signaling requires endosomal acidification and maturation, presumably because these receptors are intracellularly located (Ahmad-Nejad et al., 2002; Matsumoto et al., 2003; Akira, 2009). Similarly in FSDMC, the cytokine secretion induced by polyC (TLR3 ligand), R848 (TLR7 ligand), and CpG (TLR9 ligand) was inhibited by an inhibitor of endosomal maturation (Matsushima et al., 2004). In contrast, the mast cell response to LPS was unaffected by the treatment (Matsushima et al., 2004), in agreement with similar studies in a macrophage cell line (Ahmad-Nejad et al., 2002), presumably because TLR4 binds LPS at the cell surface.

The effect of TLR ligation on mast cell degranulation and phenotype

In addition to these findings that stimulation of mast cells with TLR agonists leads to cytokine and chemokine production and mast cell migration, some data suggest that mast cell degranulation can be induced by TLR2 ligands. Stimulation of BMMMC with PGN resulted in mast cell degranulation whereas stimulation via TLR4 did not (Supajatura et al., 2002). Similar results were obtained in human mast cells (Varadarajalu et al., 2003). Stimulation of CBMC with PGN led to histamine release in addition to cytokine release, whereas LPS stimulation caused only cytokine secretion (Varadarajalu et al., 2003). In another study using human CBMC, the degranulation induced by PGN was not found to be statistically significant, while zymosan and Pam3CSK4 induced significant degranulation (McCurdy et al., 2009). In vivo, i.d. injection of PGN but not LPS caused a mast cell-dependent increase in vascular permeability, indicating that the TLR2 ligand was inducing mast cell degranulation (Supajatura et al., 2002).

Other groups have been unable to demonstrate degranulation after stimulation of mast cells with TLR ligands, however. Neither LPS nor PGN induced degranulation of BMMMC (Ikeda and Funaba, 2003) or rat peritoneal mast cells (Wierzbički and Bezerra-Blaszczyk, 2009), and studying BMMMC and FSDMC, Matsushima et al. (2004) did not detect degranulation in response to LPS, PGN, polyIC, R848, or CpG, suggesting that signaling via TLR2–4, 7, and 9 does not cause mast cell degranulation. In agreement with these findings, TLR1/TLR2, TLR2/TLR6, and TLR4 agonists were not observed to cause degranulation of MC9.

www.frontiernain.org
July 2012 | Volume 3 | Article 185 | 5
cells or BMMMC in another study (Qiao et al., 2006). Degranulation was not observed in BMMMC or the more mature PCDMC in response to the TLR2 ligands MALP-2, LTA, or PGN (Mrabet-Dahbi et al., 2009). When these agonists were given i.p., no drop in body temperature was observed, suggesting that TLR2 activation does not lead to degranulation of mast cells in vivo (Mrabet-Dahbi et al., 2009).

It is difficult to reconcile the differences in the findings of these various studies. It may be that differences in the cell culture or isolation methods, or differences in the agonist preparations used could explain the discrepancies.

In other settings, TLR ligands have inhibited mast cell degranulation. Stimulation of LAD1 cells with dsRNA analogues resulted in decreased adhesion of the cells to fibronecin and vitronectin via TLR3, which led to a decrease in the degranulation observed when cells were allowed to adhere to these proteins (Kulka and Metcalfe, 2006). LTA and PGN acted over 24-48 h to downregulate surface levels of FceRI expression on LAD2 cells and human lung mast cells, which resulted in a decreased degranulation after antigen exposure (Yoshio et al., 2007). The effect was only partially mediated by TLR2 and was not observed with TLR4, 5, or 9 agonists (Yoshio et al., 2007).

These findings suggest that TLR signaling may affect the phenotype of mast cells, for example by downregulating FceRI expression (Yoshio et al., 2007). Human mast cells cultured in vitro in the presence of LPS or PGN had altered protease composition and cytokine production profiles (Kirschenbaum et al., 2008). In another study, LPS has been shown to cause an increase in TLR4 expression in LAD2 cells, such that increased levels of TNFα were produced after a second stimulation with LPS (Kubo et al., 2008). This is in contrast to work performed on BMMMC where classical endotoxin-tolerance was observed and cells were unresponsive to a second LPS challenge (Sly et al., 2004; Saturnino et al., 2010).

In conclusion, the ability of TLR2 agonists to cause mast cell degranulation is controversial and further work is required to clarify the situation. It seems that TLR stimulation affects the mast cell phenotype modulating the levels of receptors and proteases. Exposure of mast cells to TLR agonists in vivo, therefore, may control their ability to respond to other stimuli and the type of response that they are able to mount.

**TLR SIGNALING IN THE MAST CELL**

**LACK OF TRIF-DEPENDENT PATHWAY IN TLR SIGNALING IN THE MAST CELL**

The prototypical TLR4 ligand is LPS which is bound by the secreted protein, LPS-binding protein (LBP) and transferred to the TLR4 signaling complex by cell secreted or membrane bound CD14 (Lee et al., 2012). TLR4 acts in a complex with MD-2 (Lee et al., 2012) and this has also been shown to be the case in mast cells (Ushio et al., 2004). It is now recognized that CD14 is only required for the cell to recognize rough LPS but not smooth LPS (which contains full-length O-chaemo; Jiang et al., 2005; Huber et al., 2006; Lee et al., 2012).

Conventionally, TLR4 signaling proceeds via two signaling pathways: the MyD88-dependent and the TRIF-dependent (MyD88-independent) pathways (Lu et al., 2008; Akira, 2009; Kawai and Akira, 2010). Activation of the MyD88-dependent pathway leads to the production of pro-inflammatory cytokines via activation of AP-1, IRF-5, and NF-κB. This pathway requires the adaptor protein, TIRAP, to mediate the interaction between TLR4 and MyD88. The adaptor TRAM is required for TRIF to activate the TRIF pathway which leads to the activation of IRF-3 and, therefore, interferon-β (IFN-β) production. This pathway also causes a delayed NF-κB activation which contributes to the production of pro-inflammatory cytokines (Lu et al., 2008; Akira, 2009; Kawai and Akira, 2010).

In BMMMC, it appears that TLR4 signaling proceeds only via the MyD88-dependent pathway and that the TRIF-dependent pathway is not used (Keck et al., 2011). LPS stimulation of mast cells does not lead to IFN production (Dietrich et al., 2010; Keck et al., 2011) and TRIF deficiency does not affect the BMMC cytokine secretion induced by LPS (Keck et al., 2011). In addition, LPS-induced NF-κB activation is entirely dependent on MyD88 (Figure 2, Keck et al., 2011).

BMMMC were observed to express reduced levels of TRAM, the adaptor protein that links TRIF to the TLR4 receptor complex (Keck et al., 2011). This reduction in TRAM may prevent TLR4, and therefore LPS, from activating the TRIF pathway (Keck et al., 2011). It does not appear to fully account for the defect, however, as although TRAM over-expressing BMMC produced increased IL-6 upon LPS stimulation, IFN production was still not detected (Keck et al., 2011).

TLR4 signaling via the MyD88-dependent pathway occurs from the cell membrane, whereas TRIF-mediated signaling is believed to occur in early endosomes after internalization of the TLR4 complex (Kagan et al., 2008). TRIF is not internalized after stimulation on mast cells (Dietrich et al., 2010; Keck et al., 2011), and while in macrophages LPS is transported inside the cell, this is not the case in mast cells (Dietrich et al., 2010). It seems likely that this lack of internalization may explain why the TRIF-dependent pathway does not occur in mast cells. CD4 is required for the internalization of TLR4 (Zanoni et al., 2011; Lee et al., 2012) and although BMMC express CD14 mRNA (Ikeda and Funaba, 2003), they do not express detectable levels of CD14 on the cell surface, and CD14 must be provided in serum for the response to LPS (McCurdy et al., 2001; Varadaradjalou et al., 2003). Therefore, this lack of CD14 may explain why TLR4 is not efficiently internalized in mast cells and, therefore, why the TRIF pathway is not activated by LPS (Keck et al., 2011).

The lack of CD14 on the cell surface may not fully explain the inability of LPS to stimulate the TRIF pathway in mast cells, however, since IFNα/β production (albeit reduced) is observed upon LPS stimulation of CD14+/− macrophages suggesting that CD14-independent TRIF activation is possible (Keck et al., 2011). It is not clear whether this is due to a limited degree of CD14-independent internalization of TLR4 or if the TRIF pathway is activated from the plasma membrane in this condition (Keck et al., 2011).

The inability of LPS to stimulate the TRIF-dependent pathway is not unique to mast cells. Neutrophils stimulated with LPS similarly produce no IFN (Yamasaki et al., 2007). It has been suggested that the lack of TRIF signaling in response to LPS may be a protective mechanism to prevent excessive activation of mast cells by...
the commensal bacteria routinely encountered by the cells due to their location at sites close to the interface with the environment (Kecskeméthy et al., 2011). The same may be true for other cell types and it is not known how many other cells respond in this way to TLR4 stimulation (Tamassia et al., 2007).

In addition to its key role in TLR4 signaling, CD14 is known to be involved in the responses of other TLRs to various ligands, although the molecular details are not fully understood (Lee et al., 2012). Therefore, the lack of surface CD14 may affect the response of mast cells to TLR2 and TLR5 ligands. Since CD14 mRNA has been detected in mast cells (Iida and Funaba, 2003) it is possible that the protein is available intracellularly and may be involved with TLR3 and TLR7–9 signaling. Further studies will be required to determine CD14 intracellular expression in mast cells and what function this protein may play in TLR signaling.

Further extending these findings that LPS treatment does not cause IFNα/β secretion, Keck et al. (2011) demonstrated that neither infection with an adenoviral vector nor B-DNA transfection, both of which stimulate macrophages to produce IFNβ, caused IFN production in mast cells. Gene array analysis of human cells found that whilst a group of interferon response genes were upregulated by LPS in monocytes, this upregulation did not occur in mast cells (Okamura et al., 2003). The lack of type I IFN production upon LPS stimulation of human mast cells was confirmed by quantitative PCR, suggesting that the IFN response to LPS is lacking in human mast cells as it is in murine mast cells (Okamura et al., 2003; Keck et al., 2011).

Mast cells are not entirely defective in IFN production, however. Infection with vesicular stomatitis virus caused IFN production (Keck et al., 2011), and poly(I:C) treated human and murine mast cell secretes IFNα and IFNβ (Kulka et al., 2004) although this finding was not reproduced in a later study (Keck et al., 2011). It seems that the ability of mast cells to mount a potent IFN response is tightly regulated.

**ACTIVATION OF IRAKs**

The family of interleukin-1 receptor-associated kinases (IRAKs) are involved in the downstream signaling of TLRs (Akira, 2009; Kawai and Akira, 2010). Very little is known about their roles in TLR signaling in mast cells. In MC-9 cells, LPS and PSC were shown to activate IRAK1 in an in vitro kinase assay, suggesting that this kinase is important in signaling from TLR4 and TLR2/TLR1 (Figure 2; Qiao et al., 2006). Future studies are needed to address the roles played by IRAK1 other members of this family in TLR signal transduction in the mast cell.

**MAPK ACTIVATION BY TLR LIGANDS IN MAST CELLS**

The MAPKs are known to play a key role in TLR signaling in immune cells (Akira, 2009; Kawai and Akira, 2010) and their role in TLR signaling in the mast cell has been addressed in several studies. The involvement of p38, Erk, and Jnk in mast cell TLR signaling has been demonstrated, although there are some discrepancies between studies. There seems to be more support for a role of p38 and Jnk in the TLR signaling pathways in the mast cell than for Erk, although some studies have identified Erk as an important player. TLR4, TLR2/1, and TLR2/6 signaling activated p38 MAPK in BMMC in a comparable manner to stimulation through FcεRI (Zorn et al., 2009). Furthermore, an inhibitor of p38 reduced the IL-6 produced upon stimulation with LPS, Pam3CSK4, or FSL-1, suggesting that this kinase plays a role in TLR2 and 4 signaling (Zorn et al., 2009). Interestingly, inhibition of p38 phosphorylation caused a reduction in the secretion of IL-13 and IL-10 from BMMC upon LPS stimulation but did not reduce the mRNAs of these cytokines, suggesting that p38 regulates the production of these cytokines post-transcriptionally (Masuda et al., 2002).

In addition to p38 phosphorylation, Masuda et al. (2002) detected Jnk1/2 and p38 activation after LPS stimulation of MC-9 cells and BMCC which was similar to that induced by FcεRI signaling, together with a weaker Erk1/2 phosphorylation. In contrast, in a separate study, Jnk1/2 phosphorylation was not detected in BMMC upon LPS stimulation (Supapartjarat et al., 2001). It has been suggested that this discrepancy may be explained by the sensitivity of the assays used, since Jnk1/2 activation was demonstrated in an in vitro kinase assay in the later study while Jnk-phosphorylation was undetectable by western blot (Masuda et al., 2002). A more recent study on BMCC revealed phosphorylation of p38, Jnk1/2, and Erk1/2 after LPS stimulation but no Erk phosphorylation which was induced by stimulation of FcεRI (Li et al., 2009).

Inhibition of Jnk with curcumin reduced the amount of IL-10 and IL-13 but not IL-5 produced by BMCC and MC-9 cells upon LPS stimulation, and similar results were obtained after overexpression of a dominant negative Jnk in MC-9 cells (Masuda et al., 2002). Production of the anti-microbial peptide, CRAMP upon LPS stimulation of BMCC was not dependent on the MAPK p38, Jnk1/2, or Erk (Li et al., 2009).

The IFNα production induced upon polyI:C stimulation of human PBDMC was inhibited by pharmacological inhibitors of Jnk and p38, suggesting that these pathways are also involved in TLR3 signaling in mast cells (Kulka et al., 2004). In support of these findings, Jnk and p38 phosphorylation was observed after stimulation of human PBDMC with polyI:C (Kulka et al., 2004).

Treatment of LAI2 cells with LPS, LTA, PGN, flagellin, or CpG-containing oligonucleotides resulted in phosphorylation of Erk (Yoshioka et al., 2007). In MC-9 cells, however, neither LPS nor the TLR2/TLR1 ligand, PSC was observed to cause Erk phosphorylation while both ligands induced detectable Jnk and p38 phosphorylation (Quo et al., 2006). Specific inhibitors of all three MAPKs reduced the TNFα production induced by the ligands, suggesting that Erk does play a role in the TLR signaling in MC-9 cells, even though Erk phosphorylation was not detected (Quo et al., 2006). In a separate study, however, pharmacological inhibition of Erk phosphorylation had no effect on the IL-5, -10, or -13 secretion induced by LPS in either MC-9 or BMCC (Masuda et al., 2002).

Pam3CSK4 induced Erk-phosphorylation in BMCC that was dependent on TLR2 and MyD88, and an inhibitor of MEK, the MAPK upstream of Erk, reduced the ILT4 and PGD2 production induced by Pam3CSK4, confirming the importance of Erk in this signaling pathway in mast cells (Kikawada et al., 2007). Sustained Erk phosphorylation was not observed in mast cells deficient for the group V secretory PLA₂, and as a result the amount
of leukotriene and prostaglandin produced upon stimulation of these cells with Pam3CSK4, was reduced (Figure 2; Kikawada et al., 2007). The crucial role of the PLA2 on signaling seems to be specific to the TLR2 pathway as the deficient mast cells responded as wild-type cells to SCF and to stimulation through FcεRI (Kikawada et al., 2007).

In conclusion, it seems that p38, Jnk, and Erk are all involved in TLR signaling in the mast cell, and that their relative predominance depends on the cells and stimuli type and concentration used, as well as the particular cytokines of interest.

**REQUIREMENT FOR ADENYLYL CYCLASE**

It has been demonstrated in epithelial cells that the IL-6 production observed upon TLR4 stimulation is dependent upon the secondary messenger cAMP activating the transcription factor CREB (Song et al., 2007). Similarly in mast cells, inhibition of adenylate cyclase (AC) in CBMC reduced the IL-6 production in response to PGN and Pam3CSK4, but had no effect on the IL-1β produced (Haidl et al., 2011; Figure 2). This finding suggests that cAMP is important in the mast cells response to TLR2 stimulation, although interestingly, it may be redundant in the production of IL-1β (Haidl et al., 2011).

**CALCIUM SIGNALING AND PROTEIN KINASE ACTIVATION IN TLR SIGNALING IN THE MAST CELL**

Calcium is not thought to be involved in TLR signaling pathways (Lu et al., 2008; Akira, 2009; Kawai and Akira, 2010), but is an important secondary messenger in the FcεRI signaling pathway in the mast cell which leads to degranulation (Gillfillan and Tkaczyk, 2006). Since some studies have demonstrated that TLR ligands cause mast cell degranulation (Supajatura et al., 2002; McCurdy et al., 2003; Varadarajalu et al., 2003), while others have been unable to reproduce these findings (Ikeda and Funaba, 2003; Matsushima et al., 2004; Qiao et al., 2006; Mrabet-Dahbi et al., 2009; Wierzbiicki and Brezinska-Blaszczyk, 2009), it is perhaps not surprising that similar discrepancies exist in the literature describing the ability of TLR agonists to cause calcium release in mast cells.

In MC-9 cells and BMMC, LPS, PGN, MALP-2, and PSC were unable to induce calcium signaling (Qiao et al., 2006). In contrast, it has been shown in BMMC that PGN causes calcium mobilization which was dependent on TLR2, but LPS did not have this effect (Supajatura et al., 2002). As discussed, the discrepancies between these two studies are difficult to reconcile.

Protein kinase C (PKC) α and β appear to have no role in LPS signaling in the mast cell, since BMMC deficient in either kinase responded as well as wild-type cells to LPS, and an inhibitor of PKC had only minimal effects on the response (Zorn et al., 2009).

Similarly, PKCs do not appear to play an important role in TLR2 signaling in the mast cell, since an inhibitor of PKC did not reduce the levels of CCL2/MCP-1 produced upon Pam3CSK4 stimulation of BMMC (Murphy et al., 2007). PKD1, however, was shown to be activated in BMMC upon treatment with the TLR2 agonist, Pam3CSK4 (Figure 2; Murphy et al., 2007). The phosphorylation of PKD1 was dependent on MyD88 and reduced levels of CCL2/MCP-1 mRNA and protein were produced by cells when a PKD inhibitor was added, suggesting that the kinase is important in the response of the cells to TLR2 ligands (Murphy et al., 2007).

A more recent study in macrophages also identified a crucial role for PKD1 in MyD88-dependent TLR signal transduction (Park et al., 2009). Further work will be required to understand the roles of PKD1 and other protein kinases in TLR signaling in the mast cell.

**ROLE OF BTK IN MAST CELL TLR SIGNALING**

Bruno’s tyrosine kinase (Btk) interacts with several TLR receptors and components of the TLR signaling pathway including IRAK1 and TIRAP, and the kinase is activated by LPS in THP-1 cells (Jelferis et al., 2003). The role this kinase plays in TLR signaling is controversial. In one study, mononuclear cells from patients with mutations in Btk showed an impaired TNFα response to LPS, demonstrating that this kinase is required for TLR4 signaling (Horwood et al., 2003). Whereas, another study on monocytes from patients deficient in Btk found no such defect in TLR4 signaling (Peres de Diego et al., 2006). Murine Btk−/− macrophages produced reduced levels of IL-10 in response to several TLR agonists than wild-type cells, which resulted in an increase in the amount of IL-6 produced (Schmidt et al., 2006).

Btk is important in signaling through the FcεRI (Gillfillan and Tkaczyk, 2006), demonstrating that the tyrosine kinase is expressed and functional in mast cells. Btk does not appear to play a vital role in TLR signaling in the cells, however, since the response to TLR4, TLR2/TLR1, and TLR2/TLR6 ligands was either unaffected or enhanced in BTK-deficient mast cells (Zorn et al., 2009). Phosphorylation of p38 upon LPS stimulation was unaffected by Btk deficiency in BMMC (Zorn et al., 2009). These data suggest that the kinase may have an inhibitory role in TLR signaling in the mast cell, in contrast to the which has been described in monocytes and macrophages (Horwood et al., 2003; Schmidt et al., 2006; Zorn et al., 2009).

**ACTIVATION OF TRANSCRIPTION FACTORS**

Roles for several transcription factors have been demonstrated in TLR activation, including AP-1-binding proteins (such as c-jun and c-fos) and NF-κB (Akira, 2009; Kawai and Akira, 2010) and some of these have been implicated in TLR signaling in the mast cell.

In BMMC, LPS and PGN caused phosphorylation of IκB-α at Ser32 (Supajatura et al., 2002) which would lead to NF-κB activation. In an earlier publication, it was demonstrated that IκB-α phosphorylation after LPS stimulation only occurred in CH4/HEN BMMC and not in BMMC derived from the CH4/HEN TLR4-mutated strain, demonstrating that this activation was induced via TLR4 (Supajatura et al., 2001), and this was supported by the lack of IκB-α phosphorylation after LPS stimulation of TLR4−/− BMMC (Supajatura et al., 2002). Similarly, IκB-α phosphorylation was not observed in TLR2−/− BMMC after PGN stimulation (Supajatura et al., 2002).

A more recent study detected limited IκBα degradation upon LPS stimulation and greater levels of IκBβ degradation, particularly at time points of over an hour, confirming that NFκB signaling occurs upon TLR4 signaling in mast cells (Li et al., 2009). Inhibition of this pathway reduced the levels of transcription of
an anti-microbial peptide, demonstrating the importance of this pathway in the response (Li et al., 2009).

NF-κB signaling is also implicated in TLR signaling in human mast cells. IκB phosphorylation was detected in human PRDNC after polyIC stimulation, and the IFNα induced upon polyIC treatment of the cells was inhibited with a chemical inhibitor of NF-κB (Kožica et al., 2004). In human CBMC, PGN and Pam3CSK4 induced IL-6 and IL-10 production was inhibited by an inhibitor of IκB-κ, suggesting that the NF-κB pathway is also important in TLR2 signaling in human mast cells (Haidl et al., 2011). In agreement with these findings that NF-κB is activated upon TLR2 and TLR4 stimulation of mast cells, NF-κB-binding activity was detected in nuclear extracts of MC/9 cells after stimulation with LPS and P3C (Qiao et al., 2006).

Taken together, these studies clearly define an important role for NF-κB in TLR2 and TLR4 signal transduction in human and murine mast cells (Figure 2). P3C and LPS treatment of MC/9 cells resulted in phosphorylation of ATF-2 and, to a lesser extent, c-Jun implying that these two transcription factors are involved in the signal transduction pathways of TLR2 and 4 in mast cells (Figure 2; Qiao et al., 2006). In the same study, c-fos activity was not induced by either ligand, nor was STAT3, 5, or 6 activation detected (Qiao et al., 2006). Further work will be required to determine whether these transcription factors are activated in human and murine mast cells in addition to this cell line.

As discussed above, in stark contrast to the situation in macrophages, LPS stimulation of mast cells does not lead to IFN production (Dietrich et al., 2010; Keck et al., 2011). This is reflected in the activation of the transcription factor IRF-3 (Keck et al., 2011). In macrophages, LPS treatment causes IRF-3 phosphorylation which is not observed in BMMC, even when soluble CD14 is added to the media. When LPS is administered i.p., IRF-3 phosphorylation was observed by flow cytometry in macrophages but not mast cells, demonstrating that this difference between the two cell types also exists in vivo (Keck et al., 2011).

**EFFECT OF PI3K SIGNALING**

Phosphoinositide 3-kinase (PI3K) is composed of a p110 catalytic subunit and a p85 regulatory subunit and its action produces lipid mediators which act as secondary messengers and activate downstream kinases. The PI3K pathway is a regulator of TLR signaling depending on cell type and stimulus, as reviewed by Hazeki et al. (2007). Since PI3K activation leads to phosphorylation of the kinase AKT, AKT phosphorylation can be used as a readout for PI3K activation. AKT phosphorylation was not detected after LPS or P3C activation of MC/9 cells, suggesting that these TLR4 and TLR2 ligands do not activate the PI3K pathway in these cells (Qiao et al., 2006).

Inhibition of the PI3K pathway with two pharmacological inhibitors reduced the amount of TNFα, IL-6, and IL-10 produced by BMMC upon LPS stimulation (Shy et al., 2004). In a more recent study, however, whilst Wortmannin reduced the amount of TNFα and IL-6 produced while the IL-10 production was increased, suggesting that the pathway differentially regulates cytokine production in mast cells (Hochdorfer et al., 2011). These disparate findings regarding the role of PI3K signaling in IL-10 production are difficult to reconcile, particularly since both studies used BMMC and similar concentrations of Wortmannin (Shy et al., 2004; Hochdorfer et al., 2011). Co-treatment of cells with LPS and known PI3K stimulating factors such as IGF-1 caused an increase in the amount of TNFα produced, but inhibited the production of IL-10 in murine BMMC and PCDMC (Hochdorfer et al., 2011; Figure 2).

The differential effects of PI3K activation on TNFα and IL-10 is intriguing, and a similar result was obtained in human monocytes, in that the inhibition of PI3K differentially affected the production of two cytokines (Martin et al., 2003). When monocytes were stimulated with LPS in the presence of PI3K inhibitors, the amount of IL-12 produced was increased whilst the amount of IL-10 produced was inhibited (Martin et al., 2003). The mechanism behind the disparity appears to be that inhibition of PI3K led to suppression of Erk1/2 activation, and Erk has been previously demonstrated to cause the production of IL-10 and suppress IL-12 production in RAW264.7 cells (Yi et al., 2002). Perhaps a similar mechanism is at work in mast cells, and may explain the opposing effect that PI3K activation has on TNFα and IL-10 production.

Activation of the SCF receptor, c-kit, potently induces PI3K signaling in mast cells, and there are several mutations of the c-kit receptor which are associated with human disease that result in constitutive c-kit activation (Robin and Metcalfe, 2006). This raised the interesting possibility that mast cells in patients with particular c-kit mutations may respond differently to stimulation with LPS. Indeed, the L138.8A mast cell line which contains such a c-kit activating mutation did not produce IL-10 upon LPS stimulation unless PI3K signaling was chemically inhibited (Hochdorfer et al., 2011). It is interesting to speculate that mast cell responses to TLR agonists in vivo may be modulated by other stimuli that the cell encounters that activate the PI3K signaling pathway.

**ACTIVATION OF INHIBITORY PATHWAYS**

Several pathways that inhibit TLR signaling have been identified which presumably act to prevent over-reaction of cells to TLR ligands which could result in immune-mediated pathology (Kawai and Akira, 2010). The presence of some of these pathways has been investigated in mast cells, and several have been shown to be functional in the cells.

In macrophages, TIRAP becomes phosphorylated and degraded by SOCS1 after TLR2 and TLR4 activation, which consequently prevents further signaling via the MyD88-dependent pathway (Mansell et al., 2006). This inhibitory pathway does not occur in mast cells, however, and the levels of TIRAP remain unchanged after stimulation (Zorn et al., 2009). In mast cells, LPS activation leads to a reduction in the levels of mRNA of SOCS1 and CISH (a SOCS family member), whereas in macrophages it results in an increase in the levels of SOCS1, SOCS3, and CISH, which are thought to be responsible for the degradation of TIRAP (Mansell et al., 2006; Zorn et al., 2009).

The SH2-containing inositol phosphatase (SHIP) inhibits the NF-κB pathway during FcεRI stimulation of mast cells.
cient animals (Sly et al., 2004). SHIP inhibits signaling through the PI3K pathway (Huber et al., 1998) and since inhibition of PI3K inhibits the LPS-induced cytokine production in mast cells (Sly et al., 2004; Hochdorfer et al., 2011), it seems logical that SHIP would inhibit TLR signaling in these cells. Indeed, SHIP-mediated negative feedback has been shown to be important in the phenomenon of endotoxin-tolerance in both mast cells and macrophages, since endotoxin-tolerance could not be induced in SHIP−/− mast cells or macrophages (Sly et al., 2004). The SHIP expression in LPS stimulated mast cells and macrophages is caused by autocrine TGFβ, implying that this regulatory cytokine is important in inhibiting the response to LPS in both cell types (Sly et al., 2004).

As previously discussed, inhibition of the PI3K pathway in mast cells does not inhibit all cytokine production stimulated by LPS. Rather, the production of IL-1β was enhanced when the pathway was inhibited (Hochdorfer et al., 2011). In support of this, whilst LPS stimulation of SHIP−/− mast cells resulted in greater TNFα production, the amount of IL-1β secreted was reduced (Hochdorfer et al., 2011).

DAP12 is a transmembrane protein which has been shown to inhibit the response of macrophages to TLR agonists (Hamerman et al., 2005). DAP12−/− BMMC, however responded to TLR4, TLR2/TLR1, and TLR2/TLR6 agonists in a comparable manner to wild-type cells, suggesting that the signaling pathways in mast cells are independent of DAP12 (Sors et al., 2010).

TANK is a negative regulator of TLR signaling (Kawagoe et al., 2009) and has been identified in gene array analysis as being up-regulated in LPS stimulated mast cells (Okamura et al., 2003), raising the possibility that it may be involved in a negative feedback loop. Further work will be required to determine whether this protein indeed inhibits TLR signaling, and to establish what other pathways are important in the regulation of TLR-mediated mast cell activation.

Other as yet unidentified mechanisms may be in place to limit the response of the mast cell to LPS, or perhaps, since this does not result in IFN production (Dietrich et al., 2010; Keck et al., 2011), regulation of the mast cell LPS response is less crucial than that of macrophages. Indeed, it has been suggested that the lack of TRIF signaling in response to LPS may be a protective mechanism to prevent excessive activation of mast cells by the commensal bacteria routinely encountered by the cells due to their location at sites close to the interface with the environment (Keck et al., 2011).

**RECEPTOR CROSS-TALK BETWEEN TLRs AND OTHER RECEPTORS ON MAST CELLS**

Dectin-1 is a PRR which is known to interact with several TLRs, and behaves as a co-receptor for TLR2 (Gantner et al., 2003; Reid et al., 2009). Dectin-1 is believed to be primarily expressed on myeloid cells, and has been shown to be expressed on human mast cells (Olynych et al., 2006). Inhibition of dectin-1 reduced the LTC4 produced upon CBMC stimulation with zymosan but not PGN, and did not inhibit the production of GM-CSF or IL-1β (Olynych et al., 2006). These data suggest that the PPR is involved in mast cell recognition of zymosan, presumably in conjunction with TLR2, but not of PGN, and that the receptor is required for cell signaling to induce the production of lipid mediators but not cytokines (Olynych et al., 2006). In support of this, pharmacological inhibition of the tyrosine kinase Syk, which is activated by dectin-1, inhibited the production of LTC4 induced by zymosan and to a lesser extent by PGN. Syk is therefore important in the downstream signaling from TLR2 in mast cells (Olynych et al., 2006).

Stimulation of mast cells via TLRs results in cytokine and chemokine production in a similar way to that observed for other cells (Akira et al., 2006; Kawai and Akira, 2010). Mast cells are unique in that they express the FcεRI in addition to TLRs, and so there is the potential for cross-talk between these two cell stimulatory pathways. Several studies have addressed the impact of TLR signaling on stimulation of mast cells via the FcεRI and vice versa.

Mast cells sensitized with IgE respond more robustly to LPS stimulation (Medina-Tamayo et al., 2011). This enhanced sensitivity is not due to an increase in the expression of TLR4, CD14, or MD-2, rather the cells appear to be “pre-activated” by binding IgE and show higher basal levels of NF-κB activation (Medina-Tamayo et al., 2011). This finding adds to earlier demonstrations that IgE binding to the FcεRI activates mast cells to some extent (Kawakami and Kitaura, 2003). In addition, the anti-apoptotic effect of monomeric IgE on mast cells is synergistically enhanced by the addition of LPS, signaling via TLR4, although LPS alone had no effect on apoptosis (Jayawardana et al., 2008).

In addition to these effects, the FcεRI signaling pathway shares many features with TLR signaling, for example both pathways utilize MyD88 (Guillian and Tkaczyk, 2006; Akira, 2009; Kawai and Akira, 2010), therefore there is potential for cross-talk between the two pathways (Avila and Gonzalez-Espinoza, 2011).

The cytokine production of BMMC and MC/9 cells upon stimulation via the FcεRI receptor is synergistically enhanced in the presence of the TLR4 agonist, LPS, and the TLR2/TLR1 agonist PAM3CSK4, and to a lesser extent by that of MALP-2 and PGN (both TLR2/TLR6 agonists; Qiao et al., 2006). In contrast, the degranulation response is unaffected (Qiao et al., 2006).

Stimulation of BMMC with the TLR2 ligands MALP-2 and Pam3CSK4 synergizes with stimulation through FcεRI to enhance IL-6 production (Fehrenbach et al., 2007). MALP-2 had no effect on FcεRI-induced degranulation whereas Pam3CSK4 inhibited antigen-induced degranulation, although this was found to be due to a direct interaction between the model antigen and the lipid itself, rather than any cross-talk between signaling pathways (Fehrenbach et al., 2007).

Signaling through FcεRI induces PI3K activation in mast cells (Yano et al., 1993; Gillillan and Tkaczyk, 2006) and, as previously discussed, inhibition of the PI3K pathway during LPS stimulation results in an inhibition of IL-6 and TNFα (although the effect on IL-1β production is contentious), suggesting that this pathway acts to increase responses to LPS (Sly et al., 2004; Hochdorfer et al., 2011; Figure 2). In agreement with this, stimulation of BMMC via...
FcRI enhances the IL-6 and TNF induced by LPS, whilst inhibiting the IL-1β production (Hochdorfer et al., 2011).

In MC/9 cells, synergy has also been observed between TLR4 and FcRII induced Jnk and p38, but not Erk phosphorylation (Masuda et al., 2002; Qiao et al., 2006). The use of selective MAPK inhibitors, however, did suggest a role for Erk signaling in the synergy between the two signaling pathways (Jørgensen et al., 2006). In contrast, Smrz et al. (2010) found no evidence of synergy between FcRIc and TLR signaling in the activation of p38, Erk, or Jnk. The activation of the transcription factors, ATF-2, c-Jun, and c-Fos upon stimulation via FcRIc was increased in the presence of either TLR2 or TLR4 stimulation (Qiao et al., 2006).

Synergy was not observed for the calcium response induced by antigen, indeed, PCK was shown to inhibit the calcium release induced by mast cell activation via the FcRIc pathway by an unknown mechanism (Qiao et al., 2006). Similarly, the IRAK1 activation caused by the TLR ligands was slightly inhibited by antigen stimulation (Qiao et al., 2006).

Synergy between TLR and FcRI signaling pathways therefore has been demonstrated (Qiao et al., 2006; Figure 2), and results in enhanced cytokine secretion but not degranulation (Qiao et al., 2006; Fehrenbach et al., 2007; Hochdorfer et al., 2011). Much of this work has been performed in murine mast cells and it would be interesting to investigate the phenomenon in the human context. It has been proposed that the increased response to stimulation via FcRI in the presence of TLR2 and 4 ligands may contribute to the worsening of allergic symptoms which can occur in the presence of pathogens (Qiao et al., 2006).

CONCLUSION

Recent research identifies important roles for mast cells in the immune defense against bacteria and pathogens (Marshall, 2004; Abraham and St John, 2010) and given their locations at sites of microorganisms, in the respiratory tract, and skin, the ability of the cells to recognize invading pathogens must be crucial. A variety of PRRs are responsible for initial recognition of pathogens (Altmann et al., 2006) and of these, the TLRs are the best studied in mast cells.

Mast cells have been shown to express the majority of TLRs (Table 2) and respond to their agonists by secreting cytokines, chemokines and lipid mediators which would have a profound effect on other cells of the immune system. In addition, TLR signaling can act to enhance the response of mast cells to anti- gen, sensitizing the cells to stimulation through FcRI (Qiao et al., 2006; Fehrenbach et al., 2007; Hochdorfer et al., 2011). To date, the majority of the work investigating the function of TLRs has been performed in vitro with only a few studies in vivo (Saputjara et al., 2002; Mrabet-Dahbi et al., 2009). Further studies are therefore required to fully elucidate the role of TLR signaling in mast cells.

The signal transduction pathways triggered by TLR-stimulation of mast cells are beginning to be elucidated and have some unique features. Strikingly, the MyD88-independent pathway which leads to IFN production is not induced by TLR4 activation, which may be due to a lack of cell surface CD14 (Keck et al., 2011). Indeed, the ability of mast cells to secrete IFN in response to other TLR stimulation is somewhat controversial (Kulka et al., 2004; Keck et al., 2005). In addition, some of the inhibitory pathways which have been identified in other immune cells are not observed to occur in mast cells (Hamerman et al., 2005; Zoon et al., 2009).

As described, several discrepancies are noted in the literature reporting the signaling pathways utilized by TLRs in mast cells and the response to TLR agonists. Notably, the ability of TLR2 ligation to induce degranulation is contentious, as is the ability of mast cells to respond to TLR3 ligation and the relative importance of the different MAPK proteins in TLR signal transduction. These differences may be explained by different mast cell culture conditions resulting in heterogeneous cell populations possibly with different expression of TLRs and signaling proteins. Further work is needed to consolidate the data. Given the importance of mast cells in the immune defense to bacteria and viruses (Marshall, 2004; Abraham and St John, 2010), it is important that the signal transduction pathways utilized by TLRs and the consequences of TLR signaling in these cells are understood.

ACKNOWLEDGMENT

This work was supported by the COST Action BM1007 (Mast cells and basophils – targets for innovative therapies) of the European Community.

REFERENCES

Abraham, S. N., and St John, A. L. (2008). Mast cell-orchestrated immunity to pathogens. Nat. Rev. Immunol. 10, 440–452.

Ahmad-Nejad, P., Hacker, H., Rutz, M., Bautz, S., Kabuki, B. M., and Wagner, H. (2002). Bacterial CpG-DNA and lipopolysaccharides acti- vate Toll-like receptors at distinct cellular compartments. Mol. J. Immunol. 32, 1958–1968.

Aiki, S. (2009). Pathogen recognition by innate immunity and its signaling. Prog. Exp. Sci. Biol. Med. 85, 143–156.

Aiki, S., Uematsu, S., and Takakura, O. (2000). Pattern recognition and innate immunity. Cell 124, 783–801.

Awata, M., and Gonzalez-Enriquez, C. (2011). Signaling through Toll-like receptor 4 and mast cell-dependent innate immunity responses. EMBO J. 30, 922–929.

Blander, J. M., and Sander, L. E. (2011). Stimulation of mast cells via Fcepsilon R1 and TLR2: the type of ligand determines the outcome. Mol. Immunol. 48, 218–235.

Brzuskowiak, E., and Rüdiger, R. S. (2007). Lipotocin: a single peptide stimulating rat mast cells to cytokine and leukotriene generation and affect mast cell migration after tumor necrosis factor (TNF)-priming. J. Immunol. 179, 158–164.

Dietrich, N., Rohde, M., Geffers, R., Kroeger, A., Hauser, H., Wöien, S., and Gokuren, N. O. (2010). Mast cells exhibit proinflammatory but not type I inter- intercellular adhesion molecule-1 induced inflammatory responses upon activation of TLRs by bacteria. Proc. Natl. Acad. Sci. U.S.A. 107, 8748–8753.

Fehrenbach, K., Port, J., Grochosko, G., Kals, C., Bosker, V., Galanos, C., Kreyn, G., Frankenberg, M., and Huber, M. (2007). Stimulation of mast cells via FcγRI and TLR2: the type of ligand determines the outcome. Mol. Immunol. 44, 2057–2094.

Gilfillan, A. M., and Tkaczyk, C. (2006). Integrated signaling pathways for mast cell activation. Nat. Rev. Immunol. 6, 238–250.

Hamerman, J. A., Tchao, N. K., Lowell, C. A., and Lanser, L. L. (2005). Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. Nat. Immunol. 6, 379–386.

Hazeki, K., Nigorikawa, K., and Hazeki, O. (2007). Role of phosphoinositide
Sorathia et al. (2010) demonstrated that the PI3K pathway increases TLR-induced NF-κB activity. Inhibition of PI3K activity by Wortmannin abolished the activation of NF-κB in mast cells. Furthermore, the activation of NF-κB in mast cells was not observed after stimulation with LPS in the presence of Bortezomib, a proteasome inhibitor. This suggests that proteasome activity is required for NF-κB activation in mast cells. In conclusion, the PI3K pathway plays a crucial role in TLR-mediated NF-κB activation in mast cells.
Schmidt, N. W., Thiera, V. T., Mann, B. A., Alroy, A. N., and Kaplan, M. H. (2008). Bruton’s tyrosine kinase is required for TLR-induced IL-10 production. J. Immunol. 177, 7235–7240.

Shy, L. M., Rash, M. J., Kalesnikoff, J., Song, C. H., and Krystal, G. (2004). LPS-induced upregulation of SHIP is essential for endotoxin tolerance. Immunity 21, 227–238.

Smrz, D., Iwaki, S., Mcvicar, D. W., Sly, L. M., Rauh, M. J., Kalesnikoff, J., Schmidt, N. W., Thieu, V. T., Mann, Sandig and Bulfone-TLR signaling in mast cells

Supajatura, V., Ushio, H., Nakao, A., Supajatura, V., Ushio, H., Nakao, A., Song, J., Duncan, M. J., Li, G., Chan, C., Akira, S., Okumura, K., Ra, C., and Ogawa, H. (2002). Differential responses of mast cell Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. J. Immunol. 155, 899–906.

Wang, Z. M., Liu, C., and Dziarski, R. (2000). Chemokines are the main proinflammatory mediators in human monocytes activated by Staphylococcus aureus, peptidoglycan, and endotoxin. J. Biol. Chem. 275, 20260–20267.

Wienbeck, M., and Branestra-McHale, C. F. (2009). Distinct effects of bacterial cell wall components on mast cell degranulation, systemic leukotriene generation and migration. Microb. Immunol. 53, 688–703.

Yano, H., Nakamura, S., Kimura, K., Hanai, N., Saito, Y., Fukun, Y., Noto-mura, Y., and Matsumura, Y. (1995). Inhibition of histamine secretion by secretogranin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J. Biol. Chem. 269, 25846–25855.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 13 April 2012; accepted: 24 June 2012; published online: 04 July 2012.

Citation: Sandig H and Bulfone-Paus S (2012) TLR signaling in mast cells: common and unique features. Front. Immunol. 3:185. doi: 10.3389/fimmu.2012.00185

Copyright © 2012 Sandig and Bulfone-Paus. This article was submitted to Frontiers in Molecular Innate Immunity, a specialty section of Frontiers in Immunology. This work is licensed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.